株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌モノクローナル抗体:世界の市場および臨床試験の分析 (~2024年)

Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024

発行 PNS Pharma 商品コード 745768
出版日 ページ情報 英文 1100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌モノクローナル抗体:世界の市場および臨床試験の分析 (~2024年) Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024
出版日: 2018年11月16日 ページ情報: 英文 1100 Pages
概要

当レポートでは、世界の癌モノクローナル抗体の上市済み製品の市場と臨床パイプラインの動向を調査し、モノクローナル抗体の発展の経緯、分類・メカニズム、癌治療における重要性、適応症・企業・フェーズ別の臨床パイプライン、上市済み製品の臨床分析、競合環境と主要企業のプロファイルなどをまとめています。

第1章 イントロダクション:モノクローナル抗体

  • 開発の経緯
  • モノクローナル抗体の仕組み

第2章 モノクローナル抗体の分類

  • Naked抗体
  • 複合抗体
    • 放射標識抗体
    • 化学標識抗体
    • 免疫毒素

第3章 モノクローナル抗体のメカニズム

第4章 癌治療におけるモノクローナル抗体の重要性

第5章 世界市場の概要

  • 現在の市場シナリオ
  • 臨床パイプラインの分析

第6章 将来の展望

第7章 膀胱癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第8章 上市済み膀胱癌向けモノクローナル抗体:臨床分析

  • デュルバルマブ (Imfinzi)

第9章 血液癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第10章 上市済み血液癌向けモノクローナル抗体:臨床分析

  • ダラツムマブ (DARZALEX)
  • オファツムマブ (Arzerra)
  • オビヌツズマブ (GAZYVA・Gazyva・Gazyvaro)
  • ブリナツモマブ (Blincyto)
  • エロツズマブ (Empliciti)
  • モガムリズマブ (Poteligeo)
  • アレムツズマブ (Campath・Lemtrada・MabCampath・MabKampat・Remniq)
  • ブレンツキシマブベドチン (Adcetris)
  • イノツズマブオゾガマイシン (BESPONSA・Besponsa)
  • リツキシマブバイオシミラー (AcellBia・Acellbia・USMAL)
  • リツキシマブバイオシミラー (Blitzima・Ritemvia・Truxima・Tuxella)
  • リツキシマブバイオシミラー (Rixathon・Riximyo)
  • ゲムツズマブオゾガマイシン (Mylotarg)
  • イブリツモマブチウキセタン (Zevalin・Zevamab)
  • リツキシマブバイオシミラー (REDDITUX・Reditux・Tidecron)
  • リツキシマブバイオシミラー (Novex)
  • リツキシマブバイオシミラー (CIMAbior・RituxCIM)
  • リツキシマブ/ヒアルロニダーゼ (MabThera SC・RITUXAN SC・Rituxan Hycela)
  • リツキシマブバイオシミラー (Zytux)
  • リツキシマブバイオシミラー (RituxiRel・Toritz・Toritz RA)
  • リツキシマブバイオシミラー (Maball)
  • リツキシマブバイオシミラー (Kikuzubam)
  • リツキシマブバイオシミラー (Mabtas)

第11章 乳癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第12章 上市済み乳癌向けモノクローナル抗体:臨床分析

  • トラスツズマブ 皮下 (Herceptin SC)
  • ペルツズマブ (Omnitarg・Perjeta)
  • トラスツズマブバイオシミラー (CANMAb・Hertraz・Ogivri・Zedora)
  • トラスツズマブエムタンシン (Kadcyla)
  • トラスツズマブバイオシミラー (Vivitra)

第13章 世界の骨癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第14章 上市済み骨癌向けモノクローナル抗体:臨床分析

  • デノスマブ (PRALIA・Prolia・Ranmark・Xgeva)

第15章 脳腫瘍向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第16章 上市済み脳腫瘍向けモノクローナル抗体:臨床分析

  • ジヌツキシマブ (Unituxin)

第17章 子宮頸癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第18章 大腸癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第19章 頭頸部癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第20章 肝臓癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第21章 腎臓癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第22章 皮膚癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第23章 上市済み皮膚癌向けモノクローナル抗体:臨床分析

  • アベルマブ (BAVENCIO)
  • オララツマブ (Lartruvo)

第24章 胃癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第25章 上市済み胃癌向けモノクローナル抗体:臨床分析

  • ベバシズマブバイオシミラー (Bevax)
  • セツキシマブバイオシミラー (CinnaGen)
  • ベバシズマブバイオシミラー (Cizumab)

第26章 肺癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第27章 上市済み肺癌向けモノクローナル抗体:臨床分析

  • ネシツムマブ (Portrazza)
  • ヨードI 131デルロツキシマブビオチン (Cotara)
  • ベバシズマブバイオシミラー (Bryxta)
  • ラコツモマブ (Vaxira)
  • ラコツモマブ (Vaxira)
  • Tc 99mノフェツモマブメルペンタン (VerLuma)

第28章 卵巣癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第29章 膵癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第30章 上市済み膵癌向けモノクローナル抗体:臨床分析

  • ゲムシタビンエライダートコンパニオン診断薬 (Ventana Medical Systems・Clovis Oncology)

第31章 前立腺癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第32章 多発癌向けモノクローナル抗体の臨床パイプライン:企業・フェーズ別

第33章 上市済み多発癌向けモノクローナル抗体:臨床分析

  • セツキシマブ (Erbitux)
  • ニボルマブ (Opdivo)
  • ベバシズマブ (Avastin)
  • トラスツズマブ (Herceptin)
  • アテゾリズマブ (TECENTRIQ)
  • リツキシマブ (MabThera・Rituxan)
  • ラムシルマブ (Cyramza・Sairamza・Silamza)
  • トラスツズマブバイオシミラー (Herzuma)
  • ペンブロリズマブ (Keytruda)
  • ペンブロリズマブ Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
  • イピリムマブ (Yervoy)
  • トラスツズマブバイオシミラー (BIOMAb EGFR・CIMAher・Cimaher・Taixinsheng・TheraCIM・Theraloc・VECTHIX)
  • ニモツズマブ (BIOMAb EGFR・CIMAher・Cimaher・Taixinsheng・TheraCIM・Theraloc・VECTHIX)
  • ベバシズマブバイオシミラー (KRABEVA)
  • ベバシズマブバイオシミラー (Mvasi)
  • トラスツズマブバイオシミラー (AryoTrust)
  • サツモマブ (OncoScint CR/OV)

第34章 競合環境

  • Abbvie
  • Amgen
  • Bayer HealthCare
  • Biogen Idec
  • Eli Lilly
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Roche
  • Seattle Genetics
目次

" Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024" Report Highlights:

  • Significance for Monoclonal Antibodies for Cancer Treatment
  • Global Cancer Monoclonal Antibodies Market Overview
  • Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication
  • Global Cancer Monoclonal Antibodies Pipeline: 697 mAb
  • Marketed Cancer Monoclonal Antibodies: 60
  • Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion

The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system so as to develop more efficient mAbs.

Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body's immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together. Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient's lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies.

Table of Contents

1. Introduction to Monoclonal Antibodies

  • 1.1. History of Development
  • 1.2. Working of Monoclonal Antibodies

2. Monoclonal Antibodies Classification

  • 2.1. Naked Monoclonal Antibodies
  • 2.2. Conjugated Monoclonal Antibodies
    • 2.2.1. Radiolabeled Antibodies
    • 2.2.2. Chemolabeled Antibodies
    • 2.2.3. Immunotoxins

3. Monoclonal Antibodies Mechanisms

  • 3.1. Tumor Antigens as Targets of Antibodies
  • 3.2. Development of Antibodies for Clinical Purposes
  • 3.3. Complement Dependent Cytotoxicity (CDC)
  • 3.4. Signal Transduction Changes

4. Significance for Monoclonal Antibodies for Cancer Treatment

5. Global Cancer Monoclonal Antibodies Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Clinical Pipeline Insight

6. Global Cancer Monoclonal Antibodies Market Future Outlook

7. Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 7.1. Phase-I/II
  • 7.2. Phase-II
  • 7.3. Phase-III

8. Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight

  • 8.1. Durvalumab (Imfinzi)

9. Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 9.1. Unknown
  • 9.2. Research
  • 9.3. Preclinical
  • 9.4. Clinical
  • 9.5. Phase-I
  • 9.6. Phase-I/II
  • 9.7. Phase-II
  • 9.8. Phase-III
  • 9.9. Preregistration

10. Marketed Blood Cancer Monoclonal Antibodies Clinical Insight

  • 10.1. Daratumumab (DARZALEX)
  • 10.2. Ofatumumab (Arzerra)
  • 10.3. Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)
  • 10.4. Blinatumomab (Blincyto)
  • 10.5. Elotuzumab (Empliciti)
  • 10.6. Mogamulizumab (Poteligeo)
  • 10.7. Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
  • 10.8. Brentuximab Vedotin (Adcetris)
  • 10.9. Inotuzumab Ozogamicin (BESPONSA & Besponsa)
  • 10.10. Rituximab Biosimilar (AcellBia, Acellbia & USMAL)
  • 10.11. Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
  • 10.12. Rituximab Biosimilar (Rixathon & Riximyo)
  • 10.13. Gemtuzumab Ozogamicin (Mylotarg)
  • 10.14. Ibritumomab Tiuxetan (Zevalin & Zevamab)
  • 10.15. Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)
  • 10.16. Rituximab Biosimilar (Novex)
  • 10.17. Rituximab Biosimilar (CIMAbior & RituxCIM)
  • 10.18. Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)
  • 10.19. Rituximab Biosimilar (Zytux)
  • 10.20. Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
  • 10.21. Rituximab Biosimilar (Maball)
  • 10.22. Rituximab Biosimilar (Kikuzubam)
  • 10.23. Rituximab Biosimilar (Mabtas)

11. Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 11.1. Unknown
  • 11.2. Research
  • 11.3. Preclinical
  • 11.4. Phase-I
  • 11.5. Phase-II
  • 11.6. Phase-III
  • 11.7. Preregistration
  • 11.8. Registered

12. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight

  • 12.1. Trastuzumab Subcutaneous (Herceptin SC)
  • 12.2. Pertuzumab (Omnitarg & Perjeta)
  • 12.3. Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
  • 12.4. Trastuzumab Emtansine (Kadcyla)
  • 12.5. Trastuzumab Biosimilar (Vivitra)

13. Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 13.1. Phase-III

14. Marketed Bone Cancer Monoclonal Antibodies Clinical Insight

  • 14.1. Denosumab (PRALIA, Prolia, Ranmark & Xgeva)

15. Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 15.1. Preclinical
  • 15.2. Phase-I/II
  • 15.3. Phase-III
  • 15.4. Registered

16. Marketed Brain Cancer Monoclonal Antibodies Clinical Insight

  • 16.1. Dinutuximab (Unituxin)

17. Global - Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 17.1. Phase-I/II

18. Global - Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase

  • 18.1. Unknown
  • 18.2. Preclinical
  • 18.3. Phase-I

19. Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 19.1. Preclinical
  • 19.2. Phase-I/II
  • 19.3. Phase-III

20. Global - Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 20.1. Phase-II

21. Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 21.1. Preclinical
  • 21.2. Phase-II
  • 21.3. Phase-III

22. Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 22.1. Research
  • 22.2. Preclinical
  • 22.3. Phase-I
  • 22.4. Phase-I/II
  • 22.5. Phase-II/III
  • 22.6. Phase-III
  • 22.7. Preregistration

23. Marketed Skin Cancer Monoclonal Antibodies Clinical Insight

  • 23.1. Avelumab (BAVENCIO)
  • 23.2. Olaratumab (Lartruvo)

24. Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 24.1. Preclinical
  • 24.2. Phase-I/II
  • 24.3. Phase-II
  • 24.4. Phase-III
  • 24.5. Preregistration

25. Marketed Stomach Cancer Monoclonal Antibodies Clinical

  • 25.1. Bevacizumab Biosimilar (Bevax)
  • 25.2. Cetuximab Biosimilar - CinnaGen
  • 25.3. Bevacizumab Biosimilar (Cizumab)

26. Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 26.1. Research
  • 26.2. Clinical
  • 26.3. Phase-I
  • 26.4. Phase-I/II
  • 26.5. Phase-II
  • 26.6. Phase-II/III
  • 26.7. Phase-III
  • 26.8. Preregistration
  • 26.9. Registered

27. Marketed Lung Cancer Monoclonal Antibodies Clinical Insight

  • 27.1. Necitumumab (Portrazza)
  • 27.2. Iodine I 131 Derlotuximab Biotin (Cotara)
  • 27.3. Bevacizumab Biosimilar (Bryxta)
  • 27.4. Racotumomab (Vaxira)
  • 27.5. Racotumomab (Vaxira)
  • 27.6. Tc 99m Nofetumomab Merpentan (VerLuma)

28. Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 28.1. Research
  • 28.2. Preclinical
  • 28.3. Phase-I
  • 28.4. Phase-I/II
  • 28.5. Phase-II

29. Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 29.1. Preclinical
  • 29.2. Phase-I
  • 29.3. Phase-I/II
  • 29.4. Phase-II

30. Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight

  • 30.1. Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

31. Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 31.1. Preclinical
  • 31.2. Phase-II

32. Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  • 32.1. Unknown
  • 32.2. Research
  • 32.3. Preclinical
  • 32.4. Clinical
  • 32.5. Phase-I
  • 32.6. Phase-I/II
  • 32.7. Phase-II
  • 32.8. Phase-II/III
  • 32.9. Phase-III
  • 32.10. Registered

33. Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight

  • 33.1. Cetuximab (Erbitux)
  • 33.2. Nivolumab (Opdivo)
  • 33.3. Bevacizumab (Avastin)
  • 33.4. Trastuzumab (Herceptin)
  • 33.5. Atezolizumab (TECENTRIQ)
  • 33.6. Rituximab (MabThera & Rituxan)
  • 33.7. Ramucirumab (Cyramza, Sairamza & Silamza)
  • 33.8. Trastuzumab Biosimilar (Herzuma)
  • 33.9. Pembrolizumab (Keytruda)
  • 33.10. Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)
  • 33.11. Ipilimumab (Yervoy)
  • 33.12. Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
  • 33.13. Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)
  • 33.14. Bevacizumab Biosimilar (KRABEVA)
  • 33.15. Bevacizumab Biosimilar (Mvasi)
  • 33.16. Trastuzumab Biosimilar (AryoTrust)
  • 33.17. Satumomab (OncoScint CR/OV)

34. Competitive Landscape

  • 34.1. Abbvie
  • 34.2. Amgen
  • 34.3. Bayer HealthCare
  • 34.4. Biogen Idec
  • 34.5. Eli Lilly
  • 34.6. Genmab
  • 34.7. Gilead Sciences
  • 34.8. GlaxoSmithKline
  • 34.9. Novartis
  • 34.10. Pfizer
  • 34.11. Roche
  • 34.12. Seattle Genetics

List of Figures

  • Figure 1-1: History of Development of Monoclonal Antibodies
  • Figure 1-2: Working of Monoclonal Antibodies
  • Figure 2-1: Types of Monoclonal Antibodies
  • Figure 5-1: Global Biologics Market Classification
  • Figure 5-2: Global Market for Monoclonal Antibodies (US$ Billion), 2018-2024
  • Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-5: Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-6: Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-7: Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-8: Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-9: Global - Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-10: Global - Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-11: Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-12: Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-13: Global - Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-14: Global - Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-15: Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-16: Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-17: Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-18: Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-19: Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-20: Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-21: Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-22: Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-23: Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-24: Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-25: Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-26: Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-27: Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-28: Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-29: Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-30: Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-31: Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
  • Figure 5-32: Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-33: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024
  • Figure 5-34: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024
Back to Top